pegunigalsidase alfa

Details

Key Milestones2
Call for patient/clinician input open06-Feb-25
Call for patient/clinician input closed31-Mar-25
Submission received04-Apr-25
Submission accepted22-Apr-25
Review initiated23-Apr-25
Draft CADTH review report(s) provided to sponsor for comment08-Jul-25
Deadline for sponsors comments17-Jul-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-Aug-25
Expert committee meeting (initial)27-Aug-25
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedback18-Sep-25
End of feedback period03-Oct-25

risperidone

Details

Key Milestones2
Call for patient/clinician input openFebruary 06, 2025
Call for patient/clinician input closedMarch 31, 2025
Submission receivedMarch 21, 2025
Submission acceptedApril 04, 2025
Review initiatedApril 07, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 23, 2025
Deadline for sponsors commentsJuly 03, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorAugust 15, 2025
Expert committee meeting (initial)August 27, 2025
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedbackSeptember 18, 2025
End of feedback periodOctober 03, 2025

guselkumab

Details

Key Milestones2
Call for patient/clinician input openDecember 13, 2024
Call for patient/clinician input closedFebruary 18, 2025
Submission receivedJanuary 31, 2025
Submission acceptedFebruary 14, 2025
Review initiatedFebruary 18, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 12, 2025
Deadline for sponsors commentsMay 22, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 13, 2025
Expert committee meeting (initial)June 25, 2025
Draft recommendation issued to sponsorJuly 08, 2025
To
July 10, 2025
Draft recommendation posted for stakeholder feedbackJuly 17, 2025
End of feedback periodJuly 31, 2025

pembrolizumab

Details

Key Milestones2
Call for patient/clinician input open31-Jan-25
Call for patient/clinician input closed31-Mar-25
Submission received18-Mar-25
Submission accepted01-Apr-25
Review initiated02-Apr-25
Draft CADTH review report(s) provided to sponsor for comment18-Jun-25
Deadline for sponsors comments27-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor31-Jul-25
Expert committee meeting (initial)13-Aug-25
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedback04-Sep-25
End of feedback period18-Sep-25

asciminib

Details

Key Milestones2
Call for patient/clinician input open30-Jan-25
Call for patient/clinician input closed24-Mar-25
Submission received10-Mar-25
Submission accepted25-Mar-25
Review initiated26-Mar-25
Draft CADTH review report(s) provided to sponsor for comment11-Jun-25
Deadline for sponsors comments20-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor31-Jul-25
Expert committee meeting (initial)13-Aug-25
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedback04-Sep-25
End of feedback period18-Sep-25

glofitamab

Details

Key Milestones2
Call for patient/clinician input open29-Jan-25
Call for patient/clinician input closed24-Mar-25
Submission received07-Mar-25
Submission accepted24-Mar-25
Review initiated25-Mar-25
Draft CADTH review report(s) provided to sponsor for comment17-Jun-25
Deadline for sponsors comments26-Jun-25
CDA-AMC review report(s) and responses to comments provided to sponsor31-Jul-25
Expert committee meeting (initial)13-Aug-25
Draft recommendation issued to sponsorAugust 25, 2025
To
August 27, 2025
Draft recommendation posted for stakeholder feedback04-Sep-25
End of feedback period18-Sep-25

Non-small Cell Lung Cancer

Details

Review Type: Rapid

As per requests from jurisdictions, this project will be combined with PH0065 to be delivered together in order to streamline the process and work. Please refer to the project timelines for PH0065 .